Sanofi said it had requested a six-month review of its new drug
application by the FDA, rather than the standard 10 months.
"A large unmet medical need still exists for people with type 2
diabetes, as more than half are not at their blood sugar goal
despite using oral medications or insulin," Sanofi's diabetes head,
Pierre Chancel, said in a statement.
The latest application involves a combination of insulin glargine
with its lixisenatide drug, Sanofi said.
(Reporting by James Regan; Editing by Subhranshu Sahu)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
![](../images/ads/current/Symphony_122313.png)
![](http://archives.lincolndailynews.com/2015/Dec/23/images/ads/current/memorial_home_sda_111615.png)
|